Joseph Eid

“Internally, we obviously focused post-launch on the academic centers to make sure that hands-on experience, mechanism of action, understanding, management of patients in particular when it comes to the cytopenia, which were all of these were new for a new class of drug.”

“Scientific engagement and evidence generation remain central to how we support HCPs caring for patients with lower-risk MDS.”

“Myelodysplastic syndrome is a spectrum of disease. You have the low-risk MDS and you have the high-risk MDS. The high-risk MDS is very close to acute myelogenous leukemia.”

“You have the low risk, the high risk, which is closer to leukemia, acute myelodysplastic leukemia. patients tend to present mainly with complaints of fatigue and quality of life drop-off they get diagnosed when they have a CBC showing low hemoglobin and then a bone marrow biopsy shows that the patients have mutations…”